Phosphodiesterase type 5 inhibitors and risk of melanoma: A meta-analysis.

Abstract

BACKGROUND The association between phosphodiesterase type 5 (PDE5) inhibitors and melanoma risk is controversial. OBJECTIVE We quantify the association between use of PDE5 inhibitors and melanoma. METHODS We systematically searched PubMed, Embase, the Cochrane Central Register of Controlled Trials, Web of Science, and ClinicalTrials.gov for studies that… (More)
DOI: 10.1016/j.jaad.2017.04.1129

Topics

3 Figures and Tables

Slides referencing similar topics